Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flow from operating activities:
Net loss	$ (19,657,174)	$ (25,884,397)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,340,301	1,024,848
Vesting expense	715,938	721,269
Equity instruments issued for management, consulting, and other	205,193	450,901
Amortization of debt discount	244,830	1,246,541
Gain on valuation of equity-linked instruments	(164,902)	(1,765,907)
Income tax benefit	(661,658)	0
Gain on note receivable associated with asset purchase agreement	0	(1,290,000)
Gain on extinguishment of PPP loan	0	(541,867)
Debt extinguishment costs	(0)	1,996,681
Loss on goodwill impairment	2,813,792	12,876,498
Loss on intangible impairment	2,893,548	0
Loss on impairment of software acquired	1,249,727	0
Loss on fixed asset disposal	5,858	120,577
Changes in assets and liabilities:
Accounts receivable	(20,769)	69,913
Inventories	(98,149)	(94,715)
Prepaid expense and other assets	(194,363)	(245,526)
Accounts payable	(350,296)	(1,688,572)
Accrued expenses	(499,563)	700,966
Deferred revenue	54,548	12,644
Other liabilities	85,790	(32,414)
Net cash used in operating activities:	(12,208,929)	(12,257,732)
Cash flow from investing activities:
Acquisition of zPREDICTA, net of cash acquired	(9,590,214)	0
Purchase of fixed assets	(910,429)	(298,379)
Proceeds from sale of fixed assets	0	193,321
Acquisition of intangibles	(51,893)	(62,398)
Loan activities	(55,000)	0
Net cash used in investing activities	(10,607,536)	(167,456)
Cash flow from financing activities:
Proceeds from issuance of common stock, net	50,523,527	0
Proceeds from exercise of warrants into common stock	4,513,871	1,935,855
Proceeds from debt issuance	0	2,761,867
Repayment of debt	(4,162,744)	(1,472,389)
Payment penalties	(1,073,470)	(247,327)
Proceeds from issuance of stock pursuant to equity line	675,590	4,891,348
Issuance of common stock, prefunded warrants, warrants and exchange of warrants, net	0	5,057,919
Repurchase of common stock upon vesting of restricted stock units	(11,526)	0
Other liabilities	(124,500)	25,416
Net cash provided by financing activities	50,340,748	12,952,689
Net increase in cash and cash equivalents	27,524,283	527,501
Cash and cash equivalents at beginning of year	678,332	150,831
Cash and cash equivalents end of year	28,202,615	678,332
Non-cash transactions
Debt Conversion, Converted Instrument, Amount	0	267,328
Warrants issued pursuant to debt issuance	$ 0	$ 179,324
Shares issued pursuant to CEO note conversion and accrued interest and exchange agreement (in shares)	0	2,322,878
Shares issued pursuant to former CEO per agreement related to accrued interest	$ 143,573	$ 0
Fixed assets acquired for notes receivable and common stock	0	2,962,767
Increase to operating lease right of use asset and lease liability due to new and modified leases	77,128	1,417,077
Put and conversion derivative from debt issuance and modification	0	636,563
Inducement shares issued pursuant to convertible debt	514,011	0
Fixed assets acquired for financing arrangements	0	113,192
Cash paid during the period for:
Interest paid on debt	690,508	145,831
Conversion of Series D Preferred Stock to Common Stock [Member]
Non-cash transactions
Preferred stock conversions	0	35,000
Conversion of Series E Preferred Stock [Member]
Non-cash transactions
Preferred stock conversions	0	13,983
Stock Issued for Convertible Debt [Member]
Non-cash transactions
Shares issued pursuant to convertible debt	0	1,028,354
Stock Issued for Debt [Member]
Non-cash transactions
Shares issued pursuant to convertible debt	$ 0	$ 140,555